REAL-WORLD EFFECTIVENESS AND COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB FOR HER2-POSITIVE ADVANCED BREAST CANCER IN CHINA
Author(s)
Baolong Ding, Master of Clinical Pharmacy1, Hongting Yao, Master of Clinical Pharmacy1, Xin Li, PhD2.
1Nanjing Medical University, Nanjing, China, 2Professor, the Director of department of Clinical Pharmacy, Nanjing Medical University, Nanjing, China.
1Nanjing Medical University, Nanjing, China, 2Professor, the Director of department of Clinical Pharmacy, Nanjing Medical University, Nanjing, China.
OBJECTIVES: To evaluate the real-world effectiveness, safety, and cost-effectiveness of pertuzumab plus trastuzumab and chemotherapy compared with trastuzumab plus chemotherapy in patients with HER2-positive advanced breast cancer in China.
METHODS: Patients with HER2-positive advanced breast cancer were identified from a real-world database. Patients receiving pertuzumab plus trastuzumab and chemotherapy were assigned to the dual-targeted group, while those receiving trastuzumab plus chemotherapy were assigned to the comparator group. Propensity score matching, inverse probability of treatment weighting, and matching-adjusted indirect comparison were applied to reduce confounding. Overall survival, progression-free survival, adverse events, and cost-effectiveness were assessed.
RESULTS: A total of 1,869 patients were included, comprising 1,162 patients in the dual-targeted group and 707 patients in the comparator group. Dual HER2 blockade significantly improved survival outcomes, with median OS of 53.94 versus 37.39 months and median PFS of 17.87 versus 11.87 months. Multivariable Cox regression demonstrated reduced risks of death (HR=0.70, 95% CI 0.61-0.80) and disease progression or death (HR=0.65, 95% CI 0.59-0.72). Safety findings were consistent with the established safety profile of dual HER2 blockade. Cost-effectiveness analysis showed an incremental gain of 0.915 QALYs and an incremental cost of CNY 271,213.27, resulting in an ICER of CNY 296,303.07/QALY, which was below the willingness-to-pay threshold of three times China’s GDP per capita.
CONCLUSIONS: Pertuzumab-based dual HER2 blockade improved survival outcomes with manageable safety in real-world clinical practice. The regimen demonstrated favorable cost-effectiveness and provides real-world evidence to support treatment and reimbursement decision-making in China.
METHODS: Patients with HER2-positive advanced breast cancer were identified from a real-world database. Patients receiving pertuzumab plus trastuzumab and chemotherapy were assigned to the dual-targeted group, while those receiving trastuzumab plus chemotherapy were assigned to the comparator group. Propensity score matching, inverse probability of treatment weighting, and matching-adjusted indirect comparison were applied to reduce confounding. Overall survival, progression-free survival, adverse events, and cost-effectiveness were assessed.
RESULTS: A total of 1,869 patients were included, comprising 1,162 patients in the dual-targeted group and 707 patients in the comparator group. Dual HER2 blockade significantly improved survival outcomes, with median OS of 53.94 versus 37.39 months and median PFS of 17.87 versus 11.87 months. Multivariable Cox regression demonstrated reduced risks of death (HR=0.70, 95% CI 0.61-0.80) and disease progression or death (HR=0.65, 95% CI 0.59-0.72). Safety findings were consistent with the established safety profile of dual HER2 blockade. Cost-effectiveness analysis showed an incremental gain of 0.915 QALYs and an incremental cost of CNY 271,213.27, resulting in an ICER of CNY 296,303.07/QALY, which was below the willingness-to-pay threshold of three times China’s GDP per capita.
CONCLUSIONS: Pertuzumab-based dual HER2 blockade improved survival outcomes with manageable safety in real-world clinical practice. The regimen demonstrated favorable cost-effectiveness and provides real-world evidence to support treatment and reimbursement decision-making in China.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO170
Topic
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology